@article{018105c2b92e4c4e8fefe3ccbb58fd70,
title = "No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine",
abstract = "It is currently recommended that hydroxychloroquine (HCQ) be maintained during pregnancy in patients with systemic lupus erythematosus. Recent data suggest that this Toll-like receptor inhibitor may also reduce the recurrence rate of anti-SSA/Ro associated congenital heart block (CHB). This case report describes a unique situation in which a CHB-afflicted, HCQ-exposed pregnancy was electively terminated. The heart did not reveal any characteristic features of cardiotoxicity, providing further evidence supporting the safety of foetal exposure to HCQ.",
keywords = "Heart block, Hydroxychloroquine, Lupus, Pregnancy",
author = "Deborah Friedman and Leif Lovig and Marc Halushka and Clancy, {Robert M.} and Izmirly, {Peter M.} and Buyon, {Jill P.}",
note = "Funding Information: Funding: this study was supported by a National Institutes of Health MERIT Award (R37 AR042455, 3R37AR042455- 21S1, 3R7AR042455-21S2), The Research Registry for Neonatal Lupus (initiated with the support of National Institute of Arthritis and Musculoskeletal and Skin Diseases contract N01-AR-4-2220), a Lupus Foundation of America Lifeline grant, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R03 HD069986 and R01 HD079951). Competing interests: none declared. Publisher Copyright: {\textcopyright} Clinical and Experimental Rheumatology 2017.",
year = "2017",
language = "English (US)",
volume = "35",
pages = "857--859",
journal = "Clinical and experimental rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",
}